Preparation for restoring consciousness and calming nasal mucosa and preparation method thereof

A technology for nasal preparations, which is applied in the field of nasal preparations of pharmaceutical compositions for the treatment of cerebral apoplexy. It can solve the problems of increasing the incidence of adverse reactions and medication risks, high treatment costs, and delays in treatment, and achieves improved absorption, easy absorption, and Obvious effect of absorption

Active Publication Date: 2013-01-23
BEIJING UNIV OF CHINESE MEDICINE
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Xingnaojing Injection has the effect of cooling blood, detoxifying, resuscitating and refreshing the brain. It is an effective drug for clinical treatment of acute cerebral apoplexy. As a solubilizer, it increases the incidence of adverse reactions and the risk of medication; due to the particularity of traditional Chinese medicine injections, the administration must be used and supervised by professionals, the cost of treatment is high, and it is inconvenient to use. There is no injection by professional medical staff at the time of onset, delaying treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation for restoring consciousness and calming nasal mucosa and preparation method thereof
  • Preparation for restoring consciousness and calming nasal mucosa and preparation method thereof
  • Preparation for restoring consciousness and calming nasal mucosa and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0062] Experimental Example 1: Study on hemopharmacokinetics of the gardenia extract (prepared by the method of Example 1) in the pharmaceutical composition of the present invention combined with moxa tablets after nasal administration to rats

[0063] 25 male SD rats, weighing 250-300g, were randomly divided into 5 groups, 5 rats in each group, respectively Gardenia extract + high-concentration moxa nasal drops group (A), gardenia extract + medium-concentration Ai Pian nasal drops group (B), Gardenia extract + low concentration Ai Pian nasal drops group (C), Gardenia extract nasal drops group (D) and Gardenia extract + high concentration Ai Pian injection Group (E) fasted 12 hours before the experiment and had free access to water.

[0064] Rats in groups A, B, C, and D were given each nasal drop according to 0.1mL·kg-1 body weight (i.e. 12 mg / kg of Gardenia extract); E group was given 4 mL·kg-1 body weight (Gardenia extract 12mg / kg) tail vein injection.

[0065] Table 1: P...

experiment example 2

[0070] Experimental Example 2: Study on blood and brain pharmacokinetics of gardenia extract (prepared by the method in Example 1) in the pharmaceutical composition of the present invention combined with moxa tablet in mice after nasal administration

[0071] 160 male ICR mice, weighing 20-25g, were randomly divided into 4 groups, 40 in each group, respectively Gardenia extract + high concentration moxa nasal drops group (I), Gardenia extract + medium concentration Ai Pian nasal drops group (II), Gardenia extract + low concentration Ai Pian nasal drops group (III) and Gardenia extract nasal drops group (IV). They fasted 12 hours before the experiment and had free access to water.

[0072] Mice in groups (I), (II), (III) and (IV) were fed by 3 μL·20g -1 Body weight (ie gardenia extract 18mg / kg) was given each nasal drop.

[0073] Table 2: Hemopharmacokinetic parameters of mice in each group

[0074]

[0075] * P** P<0.01, vs Group i.v.

[0076] Depend on image 3 It ca...

experiment example 3

[0081] Experimental Example 3: Study on the pharmacokinetics of the gardenia extract (prepared by the method of Example 1) in the pharmaceutical composition of the present invention combined with moxa tablets administered to mice via different routes of administration

[0082] 120 male ICR mice, weighing 20-25g, were randomly divided into 3 groups, 40 in each group, respectively Gardenia extract + Ai Pian nasal drops group (i.n.), Gardenia extract + Ai Pian injection group (i.v.) and gardenia extract + moxa tablet oral solution group (p.o.), fasting 12h before the experiment, free to drink water.

[0083] Mice in groups (i.n.), (i.v.), and (p.o.) were given the preparations of each group through different routes, ie nasal cavity, injection and oral administration, at equal doses.

[0084] Table 4: Hemopharmacokinetic parameters of mice in each group

[0085]

[0086] * P** P<0.01, vs Group i.v.

[0087] Depend on Figure 5 The drug-time curve and the pharmacokinetic par...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation for restoring consciousness and calming nasal mucosa and a preparation method thereof. The preparation is a nasal drug composition preparation for treating cerebrovascular diseases. The nasal drug composition preparation is prepared from 30 to 50 parts by weight of borneol (or L-borneol), 3 to 9 parts by volume of synthetic musk essential oil, 2 to 6 parts by volume of turmeric root tuber essential oil and 30 to 40 parts by weight of cape jasmine fruit extract. The nasal drug composition preparation produces treatment effects through being absorbed by nasal mucosa and the nasal mucosa absorption process is mainly a passive absorption process. Drugs and fat-soluble drugs having relative molecular weight less than 1000 can be absorbed easily. The nasal drug composition preparation has high bioavailability near to 100%.

Description

field of invention [0001] The invention relates to a pharmaceutical composition preparation, in particular to a nasal preparation of a pharmaceutical composition for treating cerebral apoplexy. Background technique [0002] The pharmaceutical composition of the present invention is reformed from the traditional prescription "Angong Niuhuang Pill", and is composed of musk, borneol (artemisia argyi tablets), arborescens and turmeric. Musk has a fragrant smell, is good at running, has the effect of opening and closing, and is an essential medicine for refreshing the mind; The seeds are bitter and cold, purging the fire of the triple burner, clearing heat and cooling blood, promoting dampness and detoxification; Radix Curcuma is pungent, bitter, cold in nature, promoting blood circulation and relieving pain, promoting qi circulation and relieving depression, cooling blood and heart. [0003] Xingnaojing Injection has the effect of cooling blood, detoxifying, resuscitating and r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9066A61K9/00A61K9/06A61K9/08A61K9/107A61K9/12A61K9/127A61K9/14A61K9/70A61P9/10A61K31/045A61K31/122
Inventor 杜守颖
Owner BEIJING UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap